How outsourcing and technologies such as in-line conditioning (IC) and in-line dilution (ILD) can help prevent resource constraints, save time, and reduce manufacturing footprint and overall cost in buffer preparation.
How to understand and prepare for challenges early in development to avoid bottlenecks that significantly slow production and delay a drug’s time-to-market.
This robust purification process provides the product quality, productivity, and economics demanded by today’s downstream manufacturing.
A demonstration of a simple workflow to verify the reliability of the S3e Cell Sorter in sorting single cells.
A demonstration of the development of a robust, high-quality, and automated Multi-D chromatography purification utilizing both tandem and multi-column configurations using ChromLab™ Software on an NGC Chromatography System.
As novel medicines become a larger part of the industry's portfolio, it is critical you secure a supply chain and manufacturing processes that produce drugs in a reliable, cost-effective way.
A lot has been promised with the introduction of biosimilars, but can they really deliver a viable alternative treatment to biologics at a substantial savings?
A customer enlisted Catalent to support their child-resistant blister packaging requirements for a global Phase III study. A flexible design was created with an integrated blister card that could also support larger study requirements of 1.9 million monthly dosing cards. Through customized commercial blistering equipment a solution was provided that would accommodate the customer’s growing demands for clinical supplies.
Understand the strategies which can be employed at the different stages of development when choosing parenteral dosage forms.
Many biologics companies will partner with a contract development and manufacturing organization that can provide the required expertise and resources as well as flexibility of operations.
|
|
|
|
|
|
|
|
|